Roche Ends Arthritis Drug Trial.
Roche said Wednesday it will discontinue the development of the experimental drug, ocrelizumab, that was designed to treat patients suffering from autoimmune disease rheumatoid arthritis. Roche’s own efficacy and safety analysis of ocrelizumab showed the drug's risk profile to be unfavorable when compared to existing treatments. Goran Mijuk. Wall Street Journal. 05/19/10. (Also see: Rheumatoid Arthritis)
This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Roche Ends Arthritis Drug Trial
No replies to this topic